Syndax Pharmaceuticals SNDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$243.25M+14.8% | -$285.42M+8.4% | -$311.58M+7.0% | -$334.99M-1.1% | -$331.2M-3.9% | ||
| $49.18M+3.5% | $47.5M-2.1% | $48.55M+0.3% | $48.4M+8.7% | $44.51M+3.4% | ||
| -$278.16M+13.9% | -$322.98M-3.9% | -$310.88M-2.7% | -$302.67M-5.6% | -$286.52M-4.2% | ||
| $234.28M-19.2% | $290.04M+579% | -$60.52M-31.3% | -$46.1M— | —— | ||
| $20.66M+51.1% | $13.68M-96.1% | $355.18M+0.9% | $352M0.0% | $352.13M-0.4% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Syndax Pharmaceuticals's cash flow data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.